一般演題１４

[O14-4] 潰瘍性大腸炎患者に対する24週間のグセルクマブ皮下注導入療法の有効性と安全性：第Ⅲ相ASTRO試験

*久松 理一¹、Millie Long²、Jessica R. Allegretti³、Silvio Danese⁴、Matthew Germinaro⁵、Thomas Baker⁵、Yelina Alvarez⁵、Silke Jorgens⁵、Lingjing Jiang⁵、Hongyan Zhang⁵、吉越 真一⁶、佐々木 絢子⁶、David T. Rubin⁷、Laurent Peyrin-Biroulet⁸ (1. 杏林大学医学部 消化器内科学、2. Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill、3. Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School、4. Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele、5. Janssen Research & Development, LLC、6. Johnson & Johnson、7. University of Chicago Medicine Inflammatory Bowel Disease Centre、8. University of Lorraine, Inserm, NGERE, F-54000 Nancy, France and Groupe Hospitalier privé Ambroise Paré-Hartmann, Paris IBD Centre)